These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 16300476)

  • 1. Phosphodiesterase-4 as a potential drug target.
    Zhang KY; Ibrahim PN; Gillette S; Bollag G
    Expert Opin Ther Targets; 2005 Dec; 9(6):1283-305. PubMed ID: 16300476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclic nucleotide phosphodiesterases and their role in immunomodulatory responses: advances in the development of specific phosphodiesterase inhibitors.
    Castro A; Jerez MJ; Gil C; Martinez A
    Med Res Rev; 2005 Mar; 25(2):229-44. PubMed ID: 15514991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phosphodiesterase-4 inhibitors as a novel approach for the treatment of respiratory disease: cilomilast.
    Kroegel C; Foerster M
    Expert Opin Investig Drugs; 2007 Jan; 16(1):109-24. PubMed ID: 17155857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphodiesterase isoenzyme families in human osteoarthritis chondrocytes--functional importance of phosphodiesterase 4.
    Tenor H; Hedbom E; Häuselmann HJ; Schudt C; Hatzelmann A
    Br J Pharmacol; 2002 Feb; 135(3):609-18. PubMed ID: 11834608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent advances in PDE4 inhibitors as immunoregulators and anti-inflammatory drugs.
    Burnouf C; Pruniaux MP
    Curr Pharm Des; 2002; 8(14):1255-96. PubMed ID: 12052219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New orally active PDE4 inhibitors with therapeutic potential.
    Ochiai H; Ishida A; Ohtani T; Kusumi K; Kishikawa K; Obata T; Nakai H; Toda M
    Bioorg Med Chem Lett; 2004 Jan; 14(1):29-32. PubMed ID: 14684291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Keynote review: phosphodiesterase-4 as a therapeutic target.
    Houslay MD; Schafer P; Zhang KY
    Drug Discov Today; 2005 Nov; 10(22):1503-19. PubMed ID: 16257373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphodiesterase 9: insights from protein structure and role in therapeutics.
    Singh N; Patra S
    Life Sci; 2014 Jun; 106(1-2):1-11. PubMed ID: 24746902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of thiadiazoles as a novel structural class of potent and selective PDE7 inhibitors. Part 1: design, synthesis and structure-activity relationship studies.
    Vergne F; Bernardelli P; Lorthiois E; Pham N; Proust E; Oliveira C; Mafroud AK; Royer F; Wrigglesworth R; Schellhaas J; Barvian M; Moreau F; Idrissi M; Tertre A; Bertin B; Coupe M; Berna P; Soulard P
    Bioorg Med Chem Lett; 2004 Sep; 14(18):4607-13. PubMed ID: 15324874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of 1-benzylxanthines on cyclic AMP phosphodiesterase 4 isoenzyme.
    Suzuki H; Sawanishi H; Nomura M; Shimada T; Miyamoto K
    Biol Pharm Bull; 2006 Jan; 29(1):131-4. PubMed ID: 16394525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Behavioural effects of selective PDE4 inhibitors in relation to inhibition of catalytic activity and competition for [3H]rolipram binding.
    Kapui Z; Bence J; Boronkay E; Mikus E; Urbán Szabó K; Baranyi A; Arányi P
    Neurobiology (Bp); 1999; 7(1):71-3. PubMed ID: 10746252
    [No Abstract]   [Full Text] [Related]  

  • 12. Substituted furans as inhibitors of the PDE4 enzyme.
    Perrier H; Bayly C; Laliberté F; Huang Z; Rasori R; Robichaud A; Girard Y; Macdonald D
    Bioorg Med Chem Lett; 1999 Feb; 9(3):323-6. PubMed ID: 10091677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PDE4: arrested at the border.
    Brunton LL
    Sci STKE; 2003 Oct; 2003(204):PE44. PubMed ID: 14560046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phosphodiesterase inhibitors in airways disease.
    Fan Chung K
    Eur J Pharmacol; 2006 Mar; 533(1-3):110-7. PubMed ID: 16458289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of inhibitor binding sites of the cAMP-specific phosphodiesterase 4.
    Richter W; Unciuleac L; Hermsdorf T; Kronbach T; Dettmer D
    Cell Signal; 2001 Apr; 13(4):287-97. PubMed ID: 11306246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiple elements jointly determine inhibitor selectivity of cyclic nucleotide phosphodiesterases 4 and 7.
    Wang H; Liu Y; Chen Y; Robinson H; Ke H
    J Biol Chem; 2005 Sep; 280(35):30949-55. PubMed ID: 15994308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An Aplysia type 4 phosphodiesterase homolog localizes at the presynaptic terminals of Aplysia neuron and regulates synaptic facilitation.
    Park H; Lee JA; Lee C; Kim MJ; Chang DJ; Kim H; Lee SH; Lee YS; Kaang BK
    J Neurosci; 2005 Sep; 25(39):9037-45. PubMed ID: 16192395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Orally active PDE4 inhibitors with therapeutic potential.
    Ochiai H; Ohtani T; Ishida A; Kishikawa K; Obata T; Nakai H; Toda M
    Bioorg Med Chem Lett; 2004 Mar; 14(5):1323-7. PubMed ID: 14980691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Type 4 phosphodiesterase-dependent pathways: role in inflammatory processes.
    Jacob C; Martin-Chouly C; Lagente V
    Therapie; 2002; 57(2):163-8. PubMed ID: 12185965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phosphodiesterase type 4 expression and anti-proliferative effects in human pulmonary artery smooth muscle cells.
    Growcott EJ; Spink KG; Ren X; Afzal S; Banner KH; Wharton J
    Respir Res; 2006 Jan; 7(1):9. PubMed ID: 16423283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.